Health Care
Kevin Garcia-Galindo | 9.27.2024 4:59 PM
The U.S. Food and Drug Administration (FDA) approved a novel antipsychotic schizophrenia drug late Thursday, marking the first new treatment in decades for the mental health condition that affects 1.8 percent of the U.S. adult population.
It is a major victory for market-driven medication development. Chris Boerner, board chair and chief executive officer at Bristol Myers Squibb (BMS)—the biopharmaceutical company that created the drug—called the FDA decision a "landmark approval" and "one that has the potential to change the treatment paradigm."
Up until now, antipsychotic drugs, which address........